Impact of Restricted Reimbursement on the Use of Statins in Finland
- 1 September 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medical Care
- Vol. 48 (9), 761-766
- https://doi.org/10.1097/mlr.0b013e3181e41bcb
Abstract
New and expensive medicines are a driving force behind growth in medicine costs, and policies promoting use of less expensive products have been widely introduced. This study investigated the short-term consequences of the restricted reimbursement of expensive statins (atorvastatin and rosuvastatin) on the use of statins in Finland. Data on patients purchasing atorvastatin, rosuvastatin, or simvastatin in 2002-2007 were retrieved from the nationwide Prescription Register. Outcome measures included the time trend in the numbers of purchasers and initiators of different statins, the morbidities of new users before and after the new policy, and the proportion of users of expensive statins switching to other statins. After the restriction, the numbers of purchasers of atorvastatin and rosuvastatin dropped, and atorvastatin and rosuvastatin were seldom prescribed as first-line therapy. Before the restriction, 20.9% of new users of atorvastatin and 18.4% of those of rosuvastatin had either coronary artery disease or familial hyperlipidemia. After the restriction the corresponding figures were 28.7% and 26.8%. After the restriction new users of atorvastatin and rosuvastatin were also more likely to use other cardiovascular medicines or antidiabetics or to have previous statin purchases. A total of 57.6% of those using atorvastatin and 49.2% of those using rosuvastatin before the restriction switched to a less expensive statin. Restricted reimbursement of expensive statins decreased their use. It seems that after the policy new statin treatments have channeled appropriately. Although it is likely that the cost-containment aim of the policy was reached, health and long-term effects are not known.Keywords
This publication has 13 references indexed in Scilit:
- The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in GermanyThe European Journal of Health Economics, 2009
- Shift of statin use towards the elderly in 1995−2005: a nation‐wide register study in FinlandBritish Journal of Clinical Pharmacology, 2008
- Switching statins in Norway after new reimbursement policy – a nationwide prescription studyBritish Journal of Clinical Pharmacology, 2007
- Reference drug programs: Effectiveness and policy implicationsHealth Policy, 2007
- Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidenceHealth Policy, 2007
- Impact of Pharmaceutical Prior Authorisation PoliciesPharmacoEconomics, 2007
- Trends in Prescription Drug Expenditures by Medicaid EnrolleesMedical Care, 2006
- Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003British Journal of Clinical Pharmacology, 2005
- Changing Prescribing Patterns and Increasing Prescription Expenditures in MedicaidAnnals of Family Medicine, 2004
- European healthcare policies for controlling drug expenditure.PharmacoEconomics, 2003